Premium
Lack of Gonadal Protection by Medroxyprogesterone Acetate‐induced Transient Medical Castration during Chemotherapy for Testicular Cancer
Author(s) -
FOSSÅ SOPHIE D.,
KLEPP O.,
NORMAN N.
Publication year - 1988
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1988.tb04395.x
Subject(s) - medroxyprogesterone acetate , chemotherapy , medicine , testosterone (patch) , medroxyprogesterone , cancer , castration , spermatogenesis , hormone , testicular cancer , sperm , urology , oncology , endocrinology , andrology
Summary— The serum FSH levels were analysed in 24 testicular cancer patients 3 to 9 years after intensive chemotherapy. Sperm cell counts were performed in 12 patients. In all cases a temporary medical castration had been achieved during intensive chemotherapy by the use of medroxy‐progesterone acetate (MPA) (500 mg daily per os ). The hormone treatment was initiated on day 1 of the first chemotherapy cycle. Thirteen additional patients did not receive this hormone treatment but were treated by similar chemotherapy. The latter patients served as a control group. There was a tendency towards higher FSH levels in the MPA‐treated patients than in the controls. Following treatment, serum testosterone was significantly lower in patients who had received MPA during their intensive chemotherapy than in the controls. There was no difference between the groups with regard to recovery of sperm cell production after chemotherapy. An MPA‐induced medical castration during intensive chemotherapy in testicular cancer patients is ineffective in protecting the remaining testis against treatment‐induced damage to spermatogenesis, at least if hormone treatment is started simultaneously with chemotherapy.